Few topics in men’s health generate as much anxiety as the relationship between testosterone and the prostate. If you’ve been diagnosed with low testosterone and are considering treatment, or if you’re already on TRT, the question has almost certainly crossed your mind: is testosterone therapy going to damage my prostate? Could it cause prostate cancer?
These concerns are entirely understandable. For decades, the medical profession itself believed that testosterone fuelled prostate cancer. This belief shaped clinical guidelines, influenced prescribing decisions, and denied countless men treatment that could have significantly improved their quality of life. But the evidence has moved on considerably, and the picture that has emerged is far more reassuring than the old assumptions suggested.
This article examines what we now know about TRT and prostate health, where the historical fears came from, what current evidence actually shows, and what monitoring you should expect if you’re on testosterone therapy.
Where the Fear Came From
The belief that testosterone causes prostate cancer dates back to 1941, when Charles Huggins and Clarence Hodges published their landmark research showing that castration (which removes the body’s primary source of testosterone) caused regression of metastatic prostate cancer, and that administering testosterone to castrated men with prostate cancer caused the disease to progress.
Huggins received the Nobel Prize for this work in 1966, and his findings were genuinely revolutionary. They established the foundation of androgen deprivation therapy (ADT), which remains a cornerstone of advanced prostate cancer treatment to this day.
However, a critical logical leap was made from these findings that turned out to be incorrect: if removing testosterone slows prostate cancer, then adding testosterone must cause it. This inference seemed reasonable, and it dominated medical thinking for over six decades. It became medical orthodoxy, repeated in textbooks and clinical guidelines without rigorous challenge.
The problem is that the original inference was based on a very specific context: men who already had advanced prostate cancer, in an era when diagnostic tools were primitive by modern standards. Huggins’ original paper actually reported on just three patients. Extrapolating from the effect of testosterone on established metastatic disease to the effect of testosterone on healthy prostate tissue was a logical error, one that has taken decades to correct.
What the Current Evidence Shows
Population Studies
If testosterone caused prostate cancer, you would expect to see higher rates of the disease in men with higher testosterone levels. In fact, the opposite pattern has been observed. Multiple large epidemiological studies have found no association between higher testosterone levels and increased prostate cancer risk. Some studies have even found a slight inverse relationship, with lower testosterone levels associated with more aggressive prostate cancer when it does occur.
A particularly important analysis was the Endogenous Hormones and Prostate Cancer Collaborative Group study, published in the Journal of the National Cancer Institute, which pooled data from 18 prospective studies involving over 3,800 men with prostate cancer and 6,400 controls. The conclusion was unequivocal: there was no significant association between serum testosterone concentration and prostate cancer risk.
Furthermore, prostate cancer incidence increases with age, precisely the period of life when testosterone levels are declining, not rising. If testosterone were a major driver of prostate cancer, the disease should be most common in young men with peak testosterone levels. Instead, it is overwhelmingly a disease of older men with lower testosterone.
Clinical Trials of TRT
The strongest evidence comes from controlled clinical trials. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, was the largest randomised controlled trial of TRT ever conducted. Among its extensive safety endpoints, it specifically tracked prostate cancer incidence. Over an average follow-up of 33 months in more than 5,200 men, there was no significant increase in prostate cancer in men receiving testosterone compared to placebo.
A 2016 meta-analysis published in Medicine, which pooled data from randomised controlled trials of TRT, also found no increased risk of prostate cancer with testosterone therapy. The authors concluded that the existing evidence does not support the historical assumption that TRT increases prostate cancer risk.
The Saturation Model
The modern understanding of how testosterone interacts with prostate tissue is best explained by the saturation model, proposed by Professor Abraham Morgentaler of Harvard Medical School. This model, now widely accepted in the endocrinology community, provides a coherent explanation for why TRT doesn’t appear to increase prostate cancer risk.
The key concept is straightforward: prostate tissue has a finite number of androgen receptors. Once these receptors are saturated with testosterone, additional testosterone cannot further stimulate prostate growth. Receptor saturation occurs at a relatively low testosterone level, estimated at around 8 nmol/L (approximately 230 ng/dL).
Below the saturation point, changes in testosterone do affect the prostate. This is why castration (which drops testosterone to near-zero) causes prostate cancer to regress, and why restoring testosterone from castrate levels does stimulate growth. But above the saturation point, which includes the entire normal physiological range, changes in testosterone have no meaningful additional effect on the prostate.
Think of it like watering a plant. A wilting plant responds dramatically to water. But once the soil is saturated, pouring on more water doesn’t make the plant grow faster. The prostate’s response to testosterone works on the same principle.
This model explains several observations that were previously paradoxical:
- Why men with high-normal testosterone don’t have higher prostate cancer rates than men with low-normal testosterone
- Why TRT doesn’t increase prostate cancer risk in clinical trials
- Why androgen deprivation therapy (which drops testosterone below the saturation point) does shrink prostate cancer
- Why young men with peak testosterone levels don’t have the highest prostate cancer rates
PSA Monitoring on TRT
Even though the evidence is reassuring, PSA monitoring remains an important part of TRT management. PSA (prostate-specific antigen) is a protein produced by both normal and cancerous prostate cells. Elevated PSA levels can indicate prostate cancer, but they can also be raised by benign prostatic hyperplasia (BPH), prostatitis, urinary tract infections, and vigorous exercise.
What to Expect with PSA on TRT
When men start TRT, it’s common to see a modest rise in PSA within the first 3-12 months. This is not a sign of cancer. It reflects the normal physiological response of prostate tissue to restored testosterone levels. In most men, PSA stabilises after this initial rise and remains stable over the long term.
The British Society for Sexual Medicine (BSSM) guidelines recommend the following PSA monitoring schedule for men on TRT:
- Baseline PSA before starting TRT
- 3 months after starting treatment
- 12 months after starting treatment
- Annually thereafter
When PSA Results Require Further Investigation
Your clinician should review PSA results in context, not in isolation. Situations that may warrant further investigation include:
- A PSA level above 4.0 ng/mL (though the threshold is age-dependent and lower thresholds may apply for younger men)
- A PSA velocity greater than 0.75 ng/mL per year (a rapid rate of rise, regardless of the absolute level)
- A significant increase from baseline that cannot be explained by BPH or other benign causes
If PSA monitoring identifies a concern, the next step is typically referral to a urologist for further assessment, which may include a digital rectal examination, an MRI scan, or, if indicated, a prostate biopsy. Importantly, an elevated PSA does not mean you have cancer. Most men with elevated PSA do not have prostate cancer. But it does mean the possibility should be investigated.
Benign Prostatic Hyperplasia (BPH) and TRT
BPH, the non-cancerous enlargement of the prostate that causes urinary symptoms in many older men, is another area of concern for men considering TRT. The prostate is an androgen-sensitive organ, and it seems logical that restoring testosterone would worsen prostate enlargement and its associated symptoms: frequent urination, difficulty starting or stopping urination, weak stream, and nighttime urination.
However, the evidence is reassuring. Multiple studies have found that TRT does not significantly worsen lower urinary tract symptoms (LUTS) associated with BPH. Some studies have actually found a modest improvement in urinary symptoms in men on TRT, possibly related to improvements in detrusor muscle function or reduced bladder inflammation.
The European Association of Urology (EAU) guidelines state that BPH with moderate LUTS is not a contraindication to TRT, provided the patient is monitored appropriately. Severe, untreated LUTS may warrant urological assessment before starting testosterone therapy, but BPH alone is not a reason to withhold treatment from a man with symptomatic testosterone deficiency.
That said, if you have significant urinary symptoms, it’s important to have them assessed before starting TRT. This ensures that any underlying issues are identified and managed, and provides a baseline against which to measure any changes during treatment.
Who Should Be Cautious?
While the evidence is broadly reassuring, there are specific situations where extra caution is warranted:
Men with Active, Untreated Prostate Cancer
TRT remains contraindicated in men with known, untreated prostate cancer. While testosterone doesn’t appear to cause prostate cancer, it could potentially stimulate the growth of an existing tumour. The saturation model applies to normal prostate tissue, but cancer cells can behave differently. This is why PSA screening and, where indicated, digital rectal examination are essential before starting TRT.
Men with a History of Prostate Cancer
This is an area where the evidence is evolving and clinical opinion is shifting. Historically, a history of prostate cancer was considered an absolute contraindication to TRT. However, emerging evidence suggests that men who have been successfully treated for localised, low-risk prostate cancer may be able to receive TRT safely after an appropriate surveillance period.
Several studies, including a prospective registry study published in the Journal of Urology, have followed men with a history of treated prostate cancer who subsequently received TRT and found no increased rate of cancer recurrence. However, the evidence base is still growing, and this remains a decision that should involve both an endocrinologist and a urologist, with careful ongoing monitoring.
The BSSM guidelines note that men with a history of prostate cancer should only receive TRT after thorough discussion of risks and benefits and with enhanced monitoring. This is not a decision to make lightly or without specialist input.
Men with Significantly Elevated PSA
If your baseline PSA is elevated, your clinician should investigate the cause before starting TRT. This may involve repeating the test (PSA can be transiently elevated by infection, ejaculation, or vigorous exercise), imaging, or urological referral. Starting TRT with an unexplained elevated PSA would be imprudent, not because testosterone causes cancer, but because it’s important to rule out an existing malignancy first.
Men with a Strong Family History
Men with first-degree relatives (father or brother) who have had prostate cancer are at increased risk of developing the disease themselves. This doesn’t mean TRT is contraindicated, but it does mean that monitoring should be more vigilant. More frequent PSA testing and lower thresholds for investigation may be appropriate. Discuss your family history openly with your clinician.
What the Guidelines Say
The major clinical guidelines have evolved significantly over the past decade to reflect the evidence:
- British Society for Sexual Medicine (BSSM): States that TRT does not increase the risk of prostate cancer in men without known prostate malignancy. Recommends PSA monitoring before and during treatment.
- European Association of Urology (EAU): Concludes that there is no convincing evidence that TRT increases prostate cancer risk. Notes that men with successfully treated localised prostate cancer may be considered for TRT after appropriate surveillance.
- American Urological Association (AUA): Advises that patients should be informed that there is no definitive evidence linking TRT to the development of prostate cancer, but that monitoring is essential.
- Endocrine Society: Recommends against TRT in men with known prostate cancer but states that the evidence does not support a causal link between TRT and prostate cancer in men without known disease.
The NHS guidance on prostate cancer provides general information on screening and risk factors for men concerned about prostate health.
Regular Screening Recommendations
Whether you’re on TRT or not, prostate health screening is an important part of men’s health care, particularly from middle age onwards. For men on TRT, screening takes on additional importance as part of responsible treatment monitoring.
We recommend the following for men on testosterone therapy:
| Test | When | Purpose |
|---|---|---|
| PSA blood test | Baseline, 3 months, 12 months, then annually | Screen for changes that may warrant investigation |
| Digital rectal examination (DRE) | Baseline, then as clinically indicated | Physical assessment of prostate size and texture |
| IPSS questionnaire | Baseline, then at follow-up appointments | Track urinary symptoms related to BPH |
| Urological referral | If PSA is elevated, rising rapidly, or symptoms develop | Specialist assessment and further investigation |
The International Prostate Symptom Score (IPSS) is a simple eight-question tool that quantifies urinary symptoms. It’s useful for establishing a baseline before TRT and tracking any changes during treatment.
What Should You Do?
If you’re considering TRT or are already on treatment, here’s the practical takeaway on prostate health:
- Don’t let outdated fears prevent you from getting help. The evidence is clear that TRT, at physiological doses and with proper monitoring, does not increase prostate cancer risk in men without known prostate disease.
- Do insist on proper screening. A baseline PSA test and, where appropriate, a digital rectal examination should be performed before starting TRT. If your prescribing clinician doesn’t offer this, ask for it.
- Do maintain regular monitoring. PSA should be checked at 3 months, 12 months, and annually thereafter. This is a standard part of responsible TRT management.
- Do disclose your family history. If prostate cancer runs in your family, tell your clinician. It won’t necessarily prevent you from having TRT, but it will inform the monitoring approach.
- Don’t panic over a PSA rise. A modest increase in PSA in the first few months of TRT is normal and expected. What matters is the trend over time and the rate of change, not a single reading in isolation.
At Evernu, prostate health monitoring is built into our TRT management protocol. Our comprehensive blood testing panels include PSA as standard, and our clinicians review your results in the context of your complete clinical picture, not just as isolated numbers on a report.
If you’re experiencing symptoms of low testosterone and want to understand whether TRT might be appropriate for you, take our free testosterone screening questionnaire or visit our testosterone treatment page to learn more about how we approach testosterone therapy with thorough, evidence-based monitoring.
The Bottom Line
The relationship between testosterone and the prostate is more nuanced than the old “testosterone feeds cancer” narrative suggested. Decades of evidence, including the landmark TRAVERSE trial, have demonstrated that TRT does not increase prostate cancer risk in men without known prostate disease. The saturation model provides a coherent biological explanation for why this is the case.
None of this means monitoring is unnecessary. On the contrary, regular PSA testing and clinical assessment are essential components of responsible TRT management. But monitoring and fear are different things. You should monitor your prostate health because it’s good medical practice, not because you’re waiting for TRT to cause a problem that the evidence says it doesn’t cause.
The goal is informed confidence, not anxious avoidance. With proper screening before treatment and diligent monitoring during it, TRT and prostate health can coexist without conflict.
